HIV-Infektion

Lernziele

Überblick über:

Veränderungen des klinischen Erscheinungsbilds der HIV-Infektion in der Ära der antiretroviralen Therapie (Todesursachen, Tumore) Fortschritte der antiretroviralen Therapie Therapiebeginn, Initialtherapie und mögliche Nebenwirkungen Prävention

Literatur

• 1 Hogg R, Lima V, Sterne J A et al. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies.  Lancet. 2008;  372 293-299
• 2 Sabin C A, Worm S W, Weber R et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.  Lancet. 2008;  371 1417-1426
• 3 Lewden C, May T, Rosenthal E et al. Changes in Causes of Death Among Adults Infected by HIV Between 2000 and 2005: The „Mortalité 2000 and 2005” Surveys (ANRS EN 19 and Mortavic).  J Acquir Immune Defic Syndr. 2008;  48 590-598
• 4 Potthoff A, Brockmeyer N H. HIV-associated Kaposi's sarcoma: pathogenesis and treatment.  J Dtsch Dermatol Ges. 2009;  5 1091-1094
• 5 Deutsche AIDS-Gesellschaft (DAIG) und Österreichische AIDS-Gesellschaft .Deutsch-Österreichische Leitlinien zur antiretroviralen Therapie der HIV-Infektion. http://www.daignet.de/site-content/hiv-therapie/leitlinien-1/Leitlinien_28–05–2010_V_late.pdf Stand: März 2010
• 6 Pozniak A L, Gallant J E, DeJesus E et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes – a 96-week analysis.  J Acquir Immune Defic Syndr. 2006;  43 535-540
• 7 Cooper R D, Wiebe N, Smith N et al. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients.  Clin Infect Dis. 2010;  51 496-505
• 8 Mallal S, Phillips E, Carosi G et al. HLA-B*5701 screening for hypersensitivity to abacavir.  N Engl J Med. 2008;  358 568-579
• 9 Schiewe K. Protease inhibitor or non-nucleoside reverse transcriptase inhibitor. ACTG study 5202 in focus.  MMW Fortschr Med. 2010;  152 68-69
• 10 Clifford D B, Evans S, Yang Y et al. Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s).  HIV Clin Trials. 2009;  10 343-355
• 11 Watts D H. Teratogenicity risk of antiretroviral therapy in pregnancy.  Curr HIV/AIDS Rep. 2007;  4 135-140
• 12 Welz T, Childs K, Ibrahim F et al. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase.  AIDS. 2010;  24 1923-1928
• 13 van Leth F, Phanuphak P, Ruxrungtham K et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.  Lancet. 2004;  363 1253-1263
• 14 Molina J M, Andrade-Villanueva J, Echevarria J et al. Once daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.  Lancet. 2008;  372 646-655
• 15 Mills A M, Nelson M, Jayaweera D et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.  Aids. 2009;  23 1679-1688
• 16 Worm S W, Sabin C, Weber R et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.  J Infect Dis. 2010;  201 318-330
• 17 Pulido F, Estrada V, Baril J G et al. Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks.  HIV Clin Trials. 2009;  10 76-87
• 18 Lennox J, DeJesus E, Lazzarin A et al. Raltegravir demonstrates durable efficacy through 96 weeks: results from STARTMRK, a phase III study of raltegravir-based vs efavirenz-based therapy in treatment-naïve HIV+ patients.. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2009. Abstract H924b
• 19 Abrams D, Lévy Y, Losso M H et al. Interleukin-2 therapy in patients with HIV infection.  N Engl J Med. 2009;  361 1548-1559
• 20 ClinicalTrials.gov .University of Minnesota, Clinical and Translational Science Institute: Strategic Timing of Antiretroviral Treatment (START). http://clinicaltrials.gov/ct2/show/NCT00867048 Stand: 19.11.2010
• 21 RKI . HIV-Infektionen und AIDS-Erkrankungen in Deutschland. Jahresbericht zur Entwicklung im Jahr 2009 aus dem Robert Koch-Institut.  Epidemiologisches Bulletin. 2010;  22 205-220
• 22 D’Cruz O J, Uckun F M. Microbicides for multidrug-resistant and multitropic HIV-1.  Curr Opin Investig Drugs. 2008;  9 152-169
• 23 Karim Q A, Karim S S, Frohlich J A et al. Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women.  Science. 2010;  329 1168-1174